Stifel Financial
RCKT icon

Stifel Financial’s Rocket Pharmaceuticals RCKT Stock Holding History

Stifel Financial’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.4K Sell
27,600
-6,756
-20% -$22.5K ﹤0.01% 3620
2026
Q1 		$123K Sell
34,356
-644
-2% -$2.56K ﹤0.01% 3516
2025
Q4 		$123K Sell
35,000
-4,200
-11% -$14.4K ﹤0.01% 3462
2025
Q3 		$128K Buy
39,200
+22,850
+140% +$72K ﹤0.01% 3419
2025
Q2 		$40.1K Sell
16,350
-2,656
-14% -$13.5K ﹤0.01% 3426
2025
Q1 		$127K Sell
19,006
-1,457
-7% -$14.4K ﹤0.01% 3266
2024
Q4 		$257K Buy
20,463
+370
+2% +$5.57K ﹤0.01% 3040
2024
Q3 		$371K Sell
20,093
-490
-2% -$10K ﹤0.01% 2847
2024
Q2 		$443K Buy
20,583
+537
+3% +$12.3K ﹤0.01% 2702
2024
Q1 		$540K Buy
20,046
+709
+4% +$20.1K ﹤0.01% 2565
2023
Q4 		$580K Sell
19,337
-4,213
-18% -$93K ﹤0.01% 2481
2023
Q3 		$483K Buy
23,550
+2,034
+9% +$37K ﹤0.01% 2509
2023
Q2 		$428K Buy
21,516
+2,436
+13% +$49.2K ﹤0.01% 2609
2023
Q1 		$327K Buy
19,080
+2,548
+15% +$49.9K ﹤0.01% 2754
2022
Q4 		$324K Buy
16,532
+2,571
+18% +$47.3K ﹤0.01% 2704
2022
Q3 		$223K Buy
+13,961
New +$218K ﹤0.01% 2890

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Stifel Financial's RCKT Position: Q2 2026 in Review

Stifel Financial reduced its Rocket Pharmaceuticals (RCKT) stake by 20% in Q2 2026, selling an estimated $22.5K and leaving 27,600 shares worth $94.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3620.

Stifel Financial first reported a position in RCKT in Q3 2022 and has held it in 16 quarters since. The position peaked at $580K in Q4 2023. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Stifel Financial held 27,600 shares of Rocket Pharmaceuticals worth $94.4K as of Q2 2026.
  • Stifel Financial sold 6,756 Rocket Pharmaceuticals shares in Q2 2026, an estimated $22.5K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #3620 holding.
  • Stifel Financial first reported a position in Rocket Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Stifel Financial's Rocket Pharmaceuticals position peaked at $580K in Q4 2023.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.